泽璟制药ZG006和ZG005在ESMO年会发布临床数据

Core Viewpoint - Zai Jian Pharmaceutical announced the clinical research data and latest progress of its self-developed drugs Alveltamig (ZG006) and Nilvanstomig (ZG005) will be presented at the European Society for Medical Oncology (ESMO) annual meeting from October 17 to 21 [1] Group 1: Drug Development - ZG006 is a trispecific antibody drug developed through the company's dual/multi-specific antibody research platform, which has received clinical trial approval from both the US FDA and China's NMPA [1] - ZG006 has been included in the breakthrough therapy designation by the National Medical Products Administration (NMPA) and has been granted orphan drug status by the US FDA [1] - ZG005 is a recombinant humanized anti-PD-1/TIGIT bispecific antibody classified as a category 1 innovative tumor immunotherapy biological product, expected to be used for the treatment of various solid tumors [1]